No results for ‘’
Biocon Ltd
₹415.50
(0.40%)
Sun, 21 Jun 2026, 04:06 am
Health Technology
Pharmaceuticals: Major
24.5KBiocon EV/EBITDA Ratio
| Particulars | 2005 | 2006 | 2007 | 2008 | 2009 | 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Price to earnings ratio | 24.82 | 22.74 | 19.10 | 11.93 | 19.16 | 18.47 | 13.78 | 10.66 | 20.34 | 18.88 | 17.21 | 36.60 | 94.77 | 40.20 | 42.94 | 66.07 | 61.73 | 53.33 | 30.91 | 40.35 |
| Price to book ratio | 5.02 | 4.54 | 2.90 | 1.91 | 3.24 | 3.38 | 2.10 | 2.04 | 2.80 | 2.87 | 2.39 | 4.69 | 6.88 | 6.01 | 4.84 | 6.43 | 4.76 | 1.39 | 1.60 | 1.89 |
| Price to sales ratio | 5.47 | 4.62 | 4.07 | 1.78 | 2.37 | 2.45 | 2.30 | 2.24 | 2.95 | 3.07 | 2.83 | 5.76 | 8.75 | 6.67 | 5.16 | 6.86 | 4.89 | 2.23 | 2.15 | 2.69 |
| Price to cash flow ratio | 52.03 | 31.11 | 13.24 | 27.77 | 12.89 | 8.44 | 8.35 | 10.78 | 14.64 | 38.66 | 23.68 | 31.08 | 53.58 | 32.11 | 24.94 | 44.12 | 35.53 | 16.56 | 14.04 | 11.54 |
| Enterprise value | 4426Cr | 4736Cr | 4533Cr | 3413Cr | 6034Cr | 6723Cr | 3922Cr | 4523Cr | 7857Cr | 9512Cr | 9776Cr | 22952Cr | 35988Cr | 37534Cr | 33665Cr | 51061Cr | 43243Cr | 43592Cr | 50803Cr | 60386Cr |
| Enterprise value to EBITDA ratio | 19.61 | 17.37 | 15.40 | 10.26 | 12.53 | 11.88 | 8.17 | 8.85 | 15.22 | 17.20 | 14.89 | 26.49 | 47.90 | 27.77 | 21.70 | 30.43 | 21.40 | 14.22 | 12.10 | 18.11 |
| Debt to equity ratio | 0.12 | 0.18 | 0.18 | 0.35 | 0.30 | 0.17 | 0.10 | 0.08 | 0.29 | 0.34 | 0.62 | 0.49 | 0.44 | 0.40 | 0.40 | 0.59 | 0.61 | 1.01 | 0.82 | 0.85 |
| Return on equity % | 21.36 | 20.47 | 17.59 | 16.05 | 17.94 | 19.39 | 15.72 | 20.49 | 14.47 | 15.80 | 15.07 | 13.77 | 7.43 | 16.05 | 12.14 | 10.33 | 8.08 | 3.52 | 5.43 | 4.89 |
Biocon Ltd Enterprise Value to EBITDA Ratio
The Biocon Ltd Enterprise Value to EBITDA Ratio is a key financial metric used by investors to evaluate Biocon Ltd's valuation, profitability, and overall financial performance. Tracking the Biocon Ltd Enterprise Value to EBITDA Ratio helps investors understand whether the stock is undervalued, fairly valued, or trading at a premium compared to its historical performance and industry peers.
Biocon Ltd (NSE: BIOCON, BSE: 532523) is currently trading at ₹415.50, with a market capitalization of ₹67315.61Cr. As a leading company in the Health technology sector and Pharmaceuticals: major industry, monitoring the Biocon Ltd Enterprise Value to EBITDA Ratio is essential for fundamental analysis.
Biocon Ltd Enterprise Value to EBITDA Ratio Current Value
The current Biocon Ltd Enterprise Value to EBITDA Ratio stands at 18.11.
The latest Biocon Ltd Enterprise Value to EBITDA Ratio has increased compared to the previous period, indicating rising valuation or improved investor sentiment.
Biocon Ltd Enterprise Value to EBITDA Ratio Historical Trend
The Biocon Ltd Enterprise Value to EBITDA Ratio has shown the following historical trend:
- 2024: 18.11
- 2023: 12.10
- 2022: 14.22
- 2021: 21.40
- 2020: 30.43
The recent rise in Biocon Ltd Enterprise Value to EBITDA Ratio suggests strengthening valuation trends and improving market sentiment.
What Biocon Ltd Enterprise Value to EBITDA Ratio Indicates for Investors
The Biocon Ltd Enterprise Value to EBITDA Ratio plays a crucial role in understanding the company's financial health and valuation.
This ratio is an important metric used in fundamental analysis of Biocon Ltd.
Biocon Ltd Enterprise Value to EBITDA Ratio Analysis Summary
The Biocon Ltd Enterprise Value to EBITDA Ratio remains a crucial metric for evaluating the company's valuation and financial stability. Investors tracking Biocon Ltd Enterprise Value to EBITDA Ratio should also monitor related metrics such as P/E, P/B, EV/EBITDA, D/E, and ROE to get a complete fundamental picture.
Regular tracking of Biocon Ltd Enterprise Value to EBITDA Ratio helps investors make informed decisions based on long-term growth, valuation trends, and financial performance.